Literature DB >> 18226584

Apical membrane antigen 1: a malaria vaccine candidate in review.

Edmond J Remarque1, Bart W Faber, Clemens H M Kocken, Alan W Thomas.   

Abstract

Apical membrane antigen 1 (AMA1) is a micronemal protein of apicomplexan parasites that appears to be essential during the invasion of host cells. Immune responses to Plasmodium AMA1 can have profound parasite-inhibitory effects, both as measured in vitro and in animal challenge models, suggesting AMA1 as a potential vaccine component. However, AMA1 is polymorphic, probably as a result of immune selection operating on an important target of naturally occurring immunity. The current understanding of AMA1 will be presented, particularly in relation to the vaccine potential of AMA1 and the approaches being taken towards clinical development.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18226584     DOI: 10.1016/j.pt.2007.12.002

Source DB:  PubMed          Journal:  Trends Parasitol        ISSN: 1471-4922


  139 in total

1.  Immunological responses against Plasmodium falciparum Apical Membrane Antigen 1 vaccines vary depending on the population immunized.

Authors:  Kazutoyo Miura; Hong Zhou; Ababacar Diouf; Gregory Tullo; Samuel E Moretz; Joan A Aebig; Michael P Fay; Louis H Miller; Ogobara K Doumbo; Issaka Sagara; Alassane Dicko; Carole A Long; Ruth D Ellis
Journal:  Vaccine       Date:  2011-01-31       Impact factor: 3.641

2.  Humoral immune responses to Plasmodium falciparum among HIV-1-infected Kenyan adults.

Authors:  Obinna N Nnedu; Michael P O'Leary; Daniel Mutua; Beth Mutai; Mina Kalantari-Dehaghi; Al Jasinskas; Rie Nakajima-Sasaki; Grace John-Stewart; Phelgona Otieno; Xiaowu Liang; John Waitumbi; Francis Kimani; David Camerini; Philip L Felgner; Judd L Walson; Adam Vigil
Journal:  Proteomics Clin Appl       Date:  2011-12       Impact factor: 3.494

3.  Use of immunodampening to overcome diversity in the malarial vaccine candidate apical membrane antigen 1.

Authors:  Karen S Harris; Christopher G Adda; Madhavi Khore; Damien R Drew; Antonina Valentini-Gatt; Freya J I Fowkes; James G Beeson; Sheetij Dutta; Robin F Anders; Michael Foley
Journal:  Infect Immun       Date:  2014-08-25       Impact factor: 3.441

4.  Comparison of biological activity of human anti-apical membrane antigen-1 antibodies induced by natural infection and vaccination.

Authors:  Kazutoyo Miura; Hong Zhou; Samuel E Moretz; Ababacar Diouf; Mahamadou A Thera; Amagana Dolo; Ogobara Doumbo; Elissa Malkin; David Diemert; Louis H Miller; Gregory E D Mullen; Carole A Long
Journal:  J Immunol       Date:  2008-12-15       Impact factor: 5.422

Review 5.  Oral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells.

Authors:  Kwang-Chul Kwon; Dheeraj Verma; Nameirakpam D Singh; Roland Herzog; Henry Daniell
Journal:  Adv Drug Deliv Rev       Date:  2012-10-23       Impact factor: 15.470

6.  Phase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults.

Authors:  Mark A Pierce; Ruth D Ellis; Laura B Martin; Elissa Malkin; Eveline Tierney; Kazutoyo Miura; Michael P Fay; Joanne Marjason; Suzanne L Elliott; Gregory E D Mullen; Kelly Rausch; Daming Zhu; Carole A Long; Louis H Miller
Journal:  Vaccine       Date:  2010-01-04       Impact factor: 3.641

7.  Lack of allele-specific efficacy of a bivalent AMA1 malaria vaccine.

Authors:  Amed Ouattara; Jianbing Mu; Shannon Takala-Harrison; Renion Saye; Issaka Sagara; Alassane Dicko; Amadou Niangaly; Junhui Duan; Ruth D Ellis; Louis H Miller; Xin-zhuan Su; Christopher V Plowe; Ogobara K Doumbo
Journal:  Malar J       Date:  2010-06-21       Impact factor: 2.979

8.  Humoral immune response to mixed PfAMA1 alleles; multivalent PfAMA1 vaccines induce broad specificity.

Authors:  Kwadwo A Kusi; Bart W Faber; Alan W Thomas; Edmond J Remarque
Journal:  PLoS One       Date:  2009-12-01       Impact factor: 3.240

9.  Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02.

Authors:  Meta Roestenberg; Ed Remarque; Erik de Jonge; Rob Hermsen; Hildur Blythman; Odile Leroy; Egeruan Imoukhuede; Soren Jepsen; Opokua Ofori-Anyinam; Bart Faber; Clemens H M Kocken; Miranda Arnold; Vanessa Walraven; Karina Teelen; Will Roeffen; Quirijn de Mast; W Ripley Ballou; Joe Cohen; Marie Claude Dubois; Stéphane Ascarateil; Andre van der Ven; Alan Thomas; Robert Sauerwein
Journal:  PLoS One       Date:  2008-12-18       Impact factor: 3.240

10.  Can prenatal malaria exposure produce an immune tolerant phenotype? A prospective birth cohort study in Kenya.

Authors:  Indu Malhotra; Arlene Dent; Peter Mungai; Alex Wamachi; John H Ouma; David L Narum; Eric Muchiri; Daniel J Tisch; Christopher L King
Journal:  PLoS Med       Date:  2009-07-28       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.